154 related articles for article (PubMed ID: 36343995)
1. Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival.
Nyman SS; Ahlström H; Creusen AD; Dahlgren D; Hedeland M; Heindryckx F; Johnson U; Khaled J; Kullenberg F; Nyman R; Rorsman F; Sheikhi R; Simonsson USH; Sjögren E; Wanders A; Lennernäs H; Ebeling Barbier C
BMJ Open; 2022 Nov; 12(11):e065839. PubMed ID: 36343995
[TBL] [Abstract][Full Text] [Related]
2. Idarubicin
Roth GS; Teyssier Y; Abousalihac M; Seigneurin A; Ghelfi J; Sengel C; Decaens T
World J Gastroenterol; 2020 Jan; 26(3):324-334. PubMed ID: 31988592
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial.
Choi JW; Kim HC; Han J; Jang MJ; Chung JW
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):372-378. PubMed ID: 38147153
[TBL] [Abstract][Full Text] [Related]
4. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B
Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065
[TBL] [Abstract][Full Text] [Related]
5. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.
Anota A; Boulin M; Dabakuyo-Yonli S; Hillon P; Cercueil JP; Minello A; Jouve JL; Paoletti X; Bedenne L; Guiu B; Bonnetain F
BMJ Open; 2016 Jun; 6(6):e010696. PubMed ID: 27342239
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial.
Guiu B; Chevallier P; Assenat E; Barbier E; Merle P; Bouvier A; Dumortier J; Nguyen-Khac E; Gugenheim J; Rode A; Oberti F; Valette PJ; Yzet T; Chevallier O; Barbare JC; Latournerie M; Boulin M
Radiology; 2019 Jun; 291(3):801-808. PubMed ID: 31038408
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
8. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.
Boulin M; Hillon P; Cercueil JP; Bonnetain F; Dabakuyo S; Minello A; Jouve JL; Lepage C; Bardou M; Wendremaire M; Guerard P; Denys A; Grandvuillemin A; Chauffert B; Bedenne L; Guiu B
Aliment Pharmacol Ther; 2014 Jun; 39(11):1301-13. PubMed ID: 24738629
[TBL] [Abstract][Full Text] [Related]
9. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.
Iezzi R; Pompili M; Rinninella E; Annicchiarico E; Garcovich M; Cerrito L; Ponziani F; De Gaetano A; Siciliano M; Basso M; Zocco MA; Rapaccini G; Posa A; Carchesio F; Biolato M; Giuliante F; Gasbarrini A; Manfredi R;
Eur Radiol; 2019 Mar; 29(3):1285-1292. PubMed ID: 30171360
[TBL] [Abstract][Full Text] [Related]
10. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
Favelier S; Boulin M; Hamza S; Cercueil JP; Cherblanc V; Lepage C; Hillon P; Chauffert B; Krausé D; Guiu B
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1039-46. PubMed ID: 23224215
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.
Boulin M; Adam H; Guiu B; Aho LS; Cercueil JP; Di Martino C; Fagnoni P; Minello A; Jouve JL; Hillon P; Bedenne L; Lepage C
Dig Liver Dis; 2014 Apr; 46(4):358-62. PubMed ID: 24462550
[TBL] [Abstract][Full Text] [Related]
12. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy.
Gross A; Albrecht T
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):402-410. PubMed ID: 31705244
[TBL] [Abstract][Full Text] [Related]
13. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
14. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
[TBL] [Abstract][Full Text] [Related]
15. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
16. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma.
Sciarra A; Ronot M; Di Tommaso L; Raschioni C; Castera L; Belghiti J; Bedossa P; Vilgrain V; Roncalli M; Paradis V
Liver Int; 2015 Nov; 35(11):2466-73. PubMed ID: 25865109
[TBL] [Abstract][Full Text] [Related]
17. Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature.
Fouad M; Abdel-Rahman O
Arab J Gastroenterol; 2015 Jun; 16(2):40-5. PubMed ID: 25910573
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre.
Molinari M; Kachura JR; Dixon E; Rajan DK; Hayeems EB; Asch MR; Benjamin MS; Sherman M; Gallinger S; Burnett B; Feld R; Chen E; Greig PD; Grant DR; Knox JJ
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):684-92. PubMed ID: 17100154
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.
Tong H; Wei B; Chen S; Xie YM; Zhang MG; Zhang LH; Huang ZY; Tang CW
Oncotarget; 2017 Jul; 8(29):48303-48312. PubMed ID: 28430638
[TBL] [Abstract][Full Text] [Related]
20. Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
Welker MW; Zangos S; Kriener S; Mönch C; Zeuzem S; Trojan J
J Gastrointest Cancer; 2010 Jun; 41(2):149-52. PubMed ID: 20396977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
